Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13801 - 13825 of 14694 in total
Experimental
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to...
Investigational
Matched Description: … pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and
Experimental
Experimental
PKI-179 has been used in trials studying the treatment of Advanced Malignant Solid Tumors.
Investigational
Experimental
Experimental
Illicit
Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Investigational
Displaying drugs 13801 - 13825 of 14694 in total